Seven years after licensing BTK inhibitor from Biogen, beleaguered pennystock biotech partner concedes defeat
A BTK inhibitor Biogen punted out of its pipeline years ago has flopped its first clinical test.
Sunesis Pharma said it would not be taking vecabrutinib into the Phase II portion of its Phase Ib/II trial after reviewing initial data that suggest limited efficacy even at the highest dose. The trial had enrolled adult patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and other B-cell malignancies. The safety profile was “excellent”; it just didn’t seem to have much of an effect.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.